Atria Investments Inc Buys 5,644 Shares of Solventum Co. (NYSE:SOLV)

Atria Investments Inc raised its position in shares of Solventum Co. (NYSE:SOLV) by 93.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 11,699 shares of the company’s stock after purchasing an additional 5,644 shares during the quarter. Atria Investments Inc’s holdings in Solventum were worth $816,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Copeland Capital Management LLC bought a new position in Solventum during the third quarter worth $26,000. Mather Group LLC. bought a new stake in shares of Solventum during the 3rd quarter valued at about $27,000. EverSource Wealth Advisors LLC acquired a new stake in Solventum during the first quarter worth approximately $30,000. Hollencrest Capital Management bought a new stake in Solventum in the second quarter worth approximately $25,000. Finally, Deseret Mutual Benefit Administrators acquired a new position in Solventum in the second quarter valued at approximately $25,000.

Solventum Stock Down 0.5 %

Shares of SOLV opened at $67.12 on Tuesday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a 50 day moving average price of $70.54 and a two-hundred day moving average price of $62.20.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. The Goldman Sachs Group upped their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Stifel Nicolaus assumed coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. Wells Fargo & Company dropped their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Finally, Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.